Radiopharm Theranostics Limited
RADXNASDAQHealthcareBiotechnology
Previous close
$2.44
+$0.15 · +6.55%
RADX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
74
Undervalued
Momentum
32
Weakening
Sentiment
55
Mixed
Risk resilience
35
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRadiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- AU
- CEO
- Riccardo Canevari
- Listed since
- Dec 5, 2024
- Employees
- 14
Market position
Day range
Current $2.44
52-week range
Current $2.44
- Open
- $2.355
- Previous close
- $2.29
- Volume
- 48.85K
- 0.84× average
- Average volume
- 57.96K
- Average daily volume
- Market cap
- 3.14M USD
- Beta
- 0.8
- Market reference 1
- 50-day average
- $3.7098
- -34.23% below average
- 200-day average
- $4.5061
- -45.85% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 19.79M AUD
- EV / EBITDA
- -0.52×
- Earnings yield
- -78.40%
- Free cash flow yield
- -74.93%
Profitability & efficiency
- Return on equity
- -85.60%
- Return on assets
- -44.34%
- Return on invested capital
- -53.35%
Financial health
- Current ratio
- 2.67×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (AUD) | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 3.63M AUD | 299.23K AUD | 292.36K AUD | 8.83K AUD |
| Cost of goods sold | 3.59M AUD | — | — | — |
| Gross profit | 39.28K AUD | 299.23K AUD | 292.36K AUD | 8.83K AUD |
| Research and development | 27.52M AUD | 17.56M AUD | 13.8M AUD | 4.12M AUD |
| Selling, general, and administrative | 16.53M AUD | 15.22M AUD | 13.02M AUD | 10.85M AUD |
| Operating expenses | 38.21M AUD | 36.92M AUD | 34.8M AUD | 19.93M AUD |
| Interest income | 888.2K AUD | 50.48K AUD | 145.04K AUD | — |
| Interest expense | 65.3K AUD | 642.89K AUD | 86.09K AUD | 9.35M AUD |
| Depreciation and amortization | 7.33K AUD | 3.13M AUD | 3.3M AUD | 2.98M AUD |
| Operating income | −38.17M AUD | −36.62M AUD | −34.51M AUD | −19.92M AUD |
| Net income | −38.34M AUD | −47.95M AUD | −34.61M AUD | −30.34M AUD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$6.00
145.90% upsidePrice history unavailable
High $6.00Average $6.00Low $6.00RADX peers
Continue in GoAI
Research RADXresearch.disclaimer